A healthy lung has some capacity to regenerate itself like the liver. In COPD, these reparative mechanisms fail. HDAC therapies may be useful for COPD, as well as other airway diseases. The levels of HDAC2 expression and its activity are greatly reduced in COPD patients. Decreased HDAC activity may impair the ability of the lung epithelium to regenerate.